Ampleia
Ampleia is a French venture builder, founded in 2023, that creates and supports biotech companies developing rare-disease therapeutics, drawing on a network of 6,000+ medical and scientific experts and the AFM-Telethon ecosystem's 65+ year legacy in rare-disease R&D.
- Company typePrivate
- Founded2023
- HeadquartersÉvry, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Ampleia does
Ampleia SAS is a French venture builder founded in 2023 and headquartered in Évry-Courcouronnes (with operating presence in Paris, 75013) that builds and co-constructs biotech companies developing therapeutics for rare diseases. The firm operates a four-step disciplined approach: sourcing the best rare-disease research teams worldwide, assembling execution-focused teams of operators, scientists, and investors, advancing programs with clinical rigor, and delivering financial returns to investors and clinical benefits to patients. Its core platform is a network of 6,000+ medical and scientific experts across all technology modalities, anchored by deep operational ties to the AFM-Telethon/Genethon ecosystem, which has invested €1.7B in rare-disease R&D since 1958 and supports 38 clinical trials across 28 indications.
The company's portfolio includes legacy spin-offs Genosafe (CRO for gene and cell therapy, founded 2003), BIMR (2013, 7 companies supported with BPIfrance), Yposkesi (CDMO for gene and cell therapy, 2016), and Atamyo Therapeutics (gene therapy for muscular dystrophies, 2020), plus two current stealth-stage programs — one in immunology targeting novel metabolite transport and another in neurosciences building a large-payload gene-therapy delivery platform. The leadership team is drawn from Genethon, Sanofi, OSE Immunotherapeutics, Nanobiotix, Gensight, Imagine Institute, and AFM-Telethon, with an Investment Committee comprising Accure Therapeutics' CEO, AFM-Telethon's Operations & Innovation Director, AFM-Telethon's Scientific Director (also President of Genosafe), and the CSO of Neuvasq.
Ampleia monetizes through equity returns and licensing/royalty arrangements tied to its portfolio companies rather than direct product sales; no revenue figures, funding rounds, or external investors are publicly disclosed. GTM is enterprise field sales targeting pharma, biotech, and academic institutions in rare disease for partnership and sourcing opportunities. Customer-facing segments are research teams (primary), rare disease patients (primary beneficiary), and investors in the rare-disease space (financial beneficiaries). Distribution occurs via the firm's website (www.ampleia.eu), a monthly newsletter, thought-leadership articles, and convening events such as the Ampleia Health Innovation Summit 2026 at Station F, Paris.
Ampleia firmographics
Firmographics- Name
- Ampleia
- Legal name
- AMPLEIA SAS
- Website
- https://ampleia.eu
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ampleia is a French venture builder, founded in 2023, that creates and supports biotech companies developing rare-disease therapeutics, drawing on a network of 6,000+ medical and scientific experts and the AFM-Telethon ecosystem's 65+ year legacy in rare-disease R&D.
- Ownership category
- akta.pro rank
Ampleia industry classification
Industry- Product category
- Biotech Venture Building
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB)
Keywords
Where Ampleia is headquartered
LocationHeadquarters
- HQ city
- Évry
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Ampleia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Equity returns from portfolio companies: As a venture-builder, Ampleia generates returns through equity stakes in portfolio companies built from identifying best research teams, assembling execution-focused teams, and advancing programs through clinical development to deliver high clinical benefits to patients and meaningful financial returns to investors.
Go-to-market motion1 record
Marketing channels4 records
Ampleia product offering
Product offeringCore offering
Ampleia is a venture builder that identifies breakthrough research teams in rare diseases worldwide, assembles execution-focused teams of operators, scientists, and investors, and advances programs through clinical development to create biotech companies. The firm manages a portfolio of portfolio companies and spinoffs (Genosafe, Yposkesi, Atamyo Therapeutics) plus active stealth-stage biotechs in immunology and neurosciences, capturing equity and licensing/royalty returns while delivering clinical benefits to patients with rare diseases.
Product overview
Ampleia is a venture-builder for rare diseases that builds and co-constructs biotech companies from their earliest stages. The company operates a portfolio of ventures including Genosafe (CRO for gene and cell therapy, 2003), Yposkesi (CDMO for gene and cell therapy, 2016), and Atamyo Therapeutics (gene therapy for muscular dystrophies, 2020). Current active programs include two stealth-stage biotech companies — one developing a first-in-class therapeutic targeting novel metabolite transport in immunology, and another building a gene-therapy platform for large payload delivery in neurosciences. Ampleia identifies breakthrough science worldwide, assembles execution-focused teams, and advances programs with clinical rigor through a network of 6,000+ medical and scientific experts to deliver high clinical benefits to patients and financial returns to investors.
Differentiator
Problem solved
Functional benefit
Products and services
- Stealth Biotech (Immunology) Stealth-stage biotechnology company developing a first-in-class therapeutic targeting novel metabolite transport for immunology applications; built by Ampleia as part of its rare-disease venture-builder portfolio.
- Stealth Biotech (Neurosciences) Stealth-stage company developing a gene-therapy platform enabling large payload delivery for neurosciences applications; built by Ampleia within its rare-disease venture-builder portfolio.
- Genosafe Contract research organization (CRO) specializing in gene and cell therapy, founded in 2003; part of Ampleia's venture-builder legacy portfolio. Serge Braun serves as its President.
- Yposkesi Contract development and manufacturing organization (CDMO) for gene and cell therapy, created in 2016; part of Ampleia's venture-builder legacy portfolio.
- Atamyo Therapeutics Gene therapy company focused on muscular dystrophies, founded in 2020, advancing programs for LGMD-R5 and other rare neuromuscular diseases; built from Genethon research by Ampleia's venture builder.
Quantifiable outcome
- 218k€ annual price per patient vs 13k€ for common diseases
- +2 more outcomes
Companies that use Ampleia
Customer profileSegments3 records
Ideal customer profiles3 records
Ampleia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Ampleia partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered portfolio and core.
- Atamyo TherapeuticsportfolioAtamyo, created in 2020, focuses on gene therapy for muscular dystrophies. Pierre-Albert Colcomb was instrumental in Atamyo's creation. Portfolio company building on Genethon research.
- YposkesiportfolioYposkesi, created in 2016, is a CDMO for gene and cell therapy. Part of Ampleia's venture-builder legacy portfolio of companies.
- GenosafeportfolioGenosafe, founded in 2003, is a CRO for gene and cell therapy. Serge Braun is President of Genosafe. Part of Ampleia's venture-builder legacy.
- AFM-TelethoncoreAFM-Telethon is a renowned partner fighting rare diseases for 65+ years since 1958. They have invested €1.7b in R&D for rare diseases, have 550+ FTEs and 215k+ volunteers, and maintain a wide international network. Ampleia's legacy and track-record is deeply connected to AFM-Telethon's expertise.
- GenethoncoreGenethon, founded in 2003, is a CRO for gene and cell therapy. Ampleia President Alexandre Lemoalle is Head of Strategic Projects at Genethon. Genethon's foundational research has helped advance sarcoglycan-targeting gene therapy approaches through Atamyo Therapeutics.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Ampleia competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Ampleia social profiles
Digital presenceAmpleia compliance and trust
Trust signalCompliance1 record
Ampleia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ampleia leadership team
Management profileNumber of profiles
Profiles9 records
Ampleia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ampleia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ampleia
What does Ampleia do?
Ampleia is a venture builder that identifies breakthrough research teams in rare diseases worldwide, assembles execution-focused teams of operators, scientists, and investors, and advances programs through clinical development to create biotech companies. The firm manages a portfolio of portfolio companies and spinoffs (Genosafe, Yposkesi, Atamyo Therapeutics) plus active stealth-stage biotechs in immunology and neurosciences, capturing equity and licensing/royalty returns while delivering clinical benefits to patients with rare diseases.
Is Ampleia a public or private company?
Ampleia is a private company. It is classified as unknown and is currently operating.
When was Ampleia founded?
Ampleia was founded in 2023. It employs 1 to 10 people.
Where is Ampleia based?
Ampleia is headquartered in Évry, France, in the Europe region.
How does Ampleia make money?
One revenue line is on record: equity returns from portfolio companies.
Does Ampleia have an API?
No public API is recorded for Ampleia.
What industry is Ampleia in?
Ampleia's product category is Biotech Venture Building. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 541714 and its SIC code is 8731.